SMARCA2 and malignant colon neoplasm: This is concordant with results from Herr et al. (2010), who reported attenuated EGFR/Ras/MAPK signalling activity after reduced brm activity in the background of the dominant active EGFR mutation ElpB1. In addition, we confirmed the genetic interactions of SWI/SNF components with constitutively active KRAS in human colon cancer cells.